Nautilus Biotechnology Reports First Quarter 2025 Financial Results

"In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechnology. "The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. We are confident that 2025 will be the year that researchers begin to apply the Nautilus ...